1,119
Views
16
CrossRef citations to date
0
Altmetric
Review

Investigational glucagon-like peptide-1 agonists for the treatment of obesity

, , , &
Pages 1167-1179 | Received 20 Apr 2016, Accepted 04 Aug 2016, Published online: 26 Aug 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Elliot J. Glotfelty, Lars Olson, Tobias E. Karlsson, Yazhou Li & Nigel H. Greig. (2020) Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease. Expert Opinion on Investigational Drugs 29:6, pages 595-602.
Read now
Raymond S. Norton. (2017) Enhancing the therapeutic potential of peptide toxins. Expert Opinion on Drug Discovery 12:6, pages 611-623.
Read now
André J. Scheen. (2017) Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 503-515.
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Liraglutide for weight management: benefits and risks. Current Medical Research and Opinion 33:3, pages 537-539.
Read now

Articles from other publishers (12)

Asie Sadeghi, Maryam Niknam, Mohammad Amin Momeni-Moghaddam, Maryam Shabani, Hamid Aria, Alireza Bastin, Maryam Teimouri, Reza Meshkani & Hamed Akbari. (2023) Crosstalk between autophagy and insulin resistance: evidence from different tissues. European Journal of Medical Research 28:1.
Crossref
Felix F. Lillich, John D. Imig & Ewgenij Proschak. (2021) Multi-Target Approaches in Metabolic Syndrome. Frontiers in Pharmacology 11.
Crossref
Brandon T. Milliken, Clinton Elfers, Oleg G. Chepurny, Kylie S. Chichura, Ian R. Sweet, Tito Borner, Matthew R. Hayes, Bart C. De Jonghe, George G. Holz, Christian L. Roth & Robert P. Doyle. (2021) Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis. Journal of Medicinal Chemistry 64:2, pages 1127-1138.
Crossref
D. Weghuber, A. Forslund, H. Ahlström, A. Alderborn, K. Bergström, S. Brunner, J. Cadamuro, I. Ciba, M. Dahlbom, V. Heu, J. Hofmann, H. Kristinsson, J. Kullberg, A. Ladinger, F. B. Lagler, M. Lidström, H. Manell, M. Meirik, K. Mörwald, K. Roomp, R. Schneider, H. Vilén, K. Widhalm, F. Zsoldos & P. Bergsten. (2020) A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. Pediatric Obesity 15:7.
Crossref
Lalita Dahiya, Ramandeep Kaur, Rajiv Kumar, Manoj Kumar & Kezia Palta. (2020) GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. Current Diabetes Reviews 16:4, pages 279-292.
Crossref
Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Dong Seok Kim, Julie A. Mattison & Nigel H. Greig. (2019) Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon. Scientific Reports 9:1.
Crossref
Stefano Fiorucci, Michele Biagioli & Eleonora Distrutti. (2018) Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacological Research 134, pages 289-298.
Crossref
Yingmei Zhang, James R. Sowers & Jun Ren. (2018) Targeting autophagy in obesity: from pathophysiology to management. Nature Reviews Endocrinology 14:6, pages 356-376.
Crossref
Trevor W. Stone, Megan McPherson & L. Gail Darlington. (2018) Obesity and Cancer: Existing and New Hypotheses for a Causal Connection. eBioMedicine 30, pages 14-28.
Crossref
Yanan Shi, Xinfeng Sun, Liping Zhang, Kaoxiang Sun, Keke Li, Youxin Li & Qiang Zhang. (2018) Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice. Scientific Reports 8:1.
Crossref
Andrew J. Krentz & Gerardo Rodriguez-Araujo. (2017) Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. Pharmaceutical Medicine 31:6, pages 399-421.
Crossref
Renata Kowalczyk, Paul W. R. Harris, Geoffrey M. Williams, Sung-Hyun Yang & Margaret A. Brimble. 2017. Peptides and Peptide-based Biomaterials and their Biomedical Applications. Peptides and Peptide-based Biomaterials and their Biomedical Applications 185 227 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.